Company profile
Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06830629 | phase2 | recruiting | 2025-02-05 | 2026-09-01 | Maze Therapeutics | A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease |
| NCT05249621 | phase1 | completed | 2022-02-07 | 2022-12-21 | Maze Therapeutics | A Randomized Phase 1 of of MZE001 in Healthy Volunteers |
| NCT07694440 | phase2 | recruiting | 2026-06-23 | 2027-12-01 | Maze Therapeutics | A Study of MZE782 in Adults With PKU |
FDA applications (0)
No records yet.